The company’s EP-104GI showed remission rates of 59% at 12 weeks and up to 76% at 24 weeks.
Eupraxia Pharmaceuticals Inc. (EPRX) garnered retail attention on Tuesday after the biotech company reported positive data from the Phase 1b/2a portion of its RESOLVE trial evaluating treatment for eosinophilic esophagitis, a digestive system condition. Mid-stage trial data showed upto 76% remission with no serious safety concerns.
EPRX was among the top trending tickers on Stocktwits at the time of writing.
EP-104GI Shows Favorable Remission Rates
A new cohort using improved catheter delivery demonstrated significantly better outcomes, with the treatment well tolerated across all dose levels, with no serious adverse events. Eupraxia’s EP-104GI is backed by its Diffusphere technology, which enables precise drug delivery directly into the target tissues.
Get updates to this developing story on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
